Skip to content. | Skip to navigation

Navigation

Personal tools

Leyla Soleymani

Leyla Soleymani

Canada Research Chair in Miniaturized Biomedical Devices

Tier 2


Biography:

Department of Engineering Physics Profile | Soleymani Research Group

Research involves

Developing low-cost, miniaturized devices that can be used at point-of-care and in the field to quickly and accurately diagnose disease.

Research relevance

This research will help to provide fast and affordable healthcare services for under-served populations in Canada, and resource-poor communities in the developing world.

Making Diagnostic Testing Cheaper, Faster, More Patient-Centered

What if cancer, infectious diseases and other conditions could be diagnosed in a matter of hours instead of weeks during a regular visit to your family doctor? Or if paramedics could use a simple finger prick to analyze a heart attack victim’s blood and transmit that information to hospital before the patient’s arrival?

Point-of-care diagnostic testing promises to usher in a new era of predictive, personalized, and preemptive medicine by bringing complex diagnostic and screening tests, currently performed at centralized laboratories, to local clinics, physician offices, and patient and community homes. Yet only a few systems have made it from the research lab to market.

Leyla Soleymani, Canada Research Chair in Miniaturized Biomedical Devices, is developing new fabrication processes, materials, and devices that will enable the rapid development and commercialization of application-specific, handheld, point-of-care diagnostic systems.

She employs ink-based fabrication methods to create structurally-tuned solid-phase electronics functionalized with bio-receptors. This allows multiple biomedical devices for processing clinical samples and detecting genetic markers to be miniaturized and created on a single scalable and inexpensive system.

Her research has already contributed to a novel biosensor that improves the detection of viruses and bacteria. Dubbed as the most sensitive nanostructured biosensing chip of its kind, the device's probes can identify whether a particular disease exists within the body with the utmost precision and within only 30 minutes.

Offering sensitive, specific, low-cost, and easily-accessible disease diagnosis, prognosis, and treatment selection capabilities at the point-of-need, promises significant health care benefits for under-served populations in Canada and resource-poor communities in the developing world.